News Release：2025 | Eisai Co., Ltd.

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2025 Release

August 18, 2025

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
July 31, 2025

Revenue of LEQEMBI® (Preliminary Basis)
July 31, 2025

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease

56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four Years
July 31, 2025

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer’s disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation
July 31, 2025

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025

LENVIMA® (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025

Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025

Launch of Beova® Tablets in Thailand for Overactive Bladder
July 22, 2025

Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer’s Association International Conference 2025
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD
AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition
July 16, 2025

Eisai Awarded “The 9th Bioindustry Award”
for Drug Discovery Research for Anti- Amyloid β Monoclonal Antibody Lecanemab
July 14, 2025

“URECE®” (Dotinurad) Launched in China as a treatment for Gout
July 9, 2025

Update on the Cost-Effectiveness Evaluation of LEQEMBI® by the Central Social Insurance Medical Council of Japan’s Ministry of Health, Labour and Welfare
July 8, 2025

Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
June 2, 2025

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan
- Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product -
May 29, 2025

Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.
May 27, 2025

New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
May 21, 2025

Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 16, 2025

Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro®
May 15, 2025

Notification Regarding Partial Amendment to the Articles of Incorporation
May 8, 2025

Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
May 1, 2025

REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
April 29, 2025

Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
April 16, 2025

Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology
Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD
April 14, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
April 1, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
March 28, 2025

“New Answers to Dementia”
Eisai Launches Corporate Awareness Campaign
March 28, 2025

EISAI TO DIVEST RIGHTS FOR PARIET® IN CHINA TO PEAK PHARMA
March 27, 2025

Eisai to Divest Rights for Warfarin in Japan to Sawai
March 27, 2025

Eisai to Present the Latest Research Results, Including Long-Term and
Real-Word Data on Lecanemab and Biomarkers for Alzheimer’s Disease at the AD/PD™ 2025 Annual Meeting
March 25, 2025

World’s First Early Alzheimer’s Disease Treatment Developed in Japan LEQEMBI® Receives Prime Minister’s Award at the 12th Technology Management and Innovation Awards
March 24, 2025

EISAI SELECTED AS A NADESHIKO BRAND 2025 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE
March 21, 2025

Proton Pump Inhibitor “Pariet® S” Approved in Japan as RX-to-OTC Switch
Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product
March 14, 2025

Notice Concerning Commencement of Tender Offer by Eisai Co., Ltd. for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
March 10, 2025

EISAI RECOGNIZED AS “2025 KENKO INVESTMENT FOR HEALTH” FOR THE FIRST TIME AND CERTIFIED AS “OUTSTANDING ORGANIZATION OF KENKO INVESTMENT FOR HEALTH PROGRAM (WHITE 500)” FOR THE SIXTH TIME
March 7, 2025

Eisai Announces Appointments of Corporate Officers
March 7, 2025

Notice of Nominees for Directors
March 7, 2025

Notification Regarding Changes in Representative Corporate Officers
March 4, 2025

UPDATE ON THE CO-PROMOTION OF THE ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG IN JAPAN
March 3, 2025

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
March 3, 2025

“Fatigue Recovery While You Sleep!” Eisai to Launch Designated Quasi-Drug Drink “Chocola BB® Nightwell”
Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine
February 28, 2025

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
February 28, 2025

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
February 20, 2025

EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2024” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY” FOR SECOND CONSECUTIVE YEAR,
AS A COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
February 14, 2025

DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION FOR EARLY SCREENING OF ALZHEIMER’S DISEASE
MACHINE LEARNING MODEL USING DATA THAT CAN BE COLLECTED IN DAILY MEDICAL EXAMINATIONS BY PRIMARY CARE PHYSICIANS
February 6, 2025

Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security
February 3, 2025

Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
January 31, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
January 27, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of
Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy
January 24, 2025

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-015 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
January 23, 2025

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”
January 22, 2025

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE NINTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
January 14, 2025

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience
of a subcutaneous injection with at-home administration option
January 7, 2025

Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer’s Disease